Columbia University

MTX110 shows promising survival outcomes in recurrent glioblastoma, with patients achieving 12-13 months OS and 6-12 months PFS, using a novel CED delivery system.

Columbia researchers engineered probiotic bacteria to educate the immune system to destroy cancer cells, potentially leading to personalized cancer vaccines. The bacterial vaccine, tested in mouse models, effectively suppressed or eliminated primary and metastatic cancers while leaving healthy tissues unharmed. Published in *Nature*, the study highlights the vaccine's efficacy over traditional peptide-based cancer vaccines and its potential to prevent cancer recurrence.

A network of 25 European medical schools aims to train 10,000 students on climate change health impacts over three years, addressing gaps in current curricula.

New York Gov. Kathy Hochul announced the Empire AI consortium, a group of seven research institutions aiming to advance AI for public good, funded by over $400 million. The consortium, led by Dr. Robert J. Harrison, will focus on issues like climate change, drug discovery, and cybersecurity, addressing the lack of access to high-performance computing for AI research.

Hundreds gathered to celebrate Roy Vagelos' scientific accomplishments and his support for Columbia University, featuring a Broadway musical performance. Vagelos' contributions include revolutionizing drug discovery, leading Merck, and founding the Division of Biology and Biomedical Sciences. A tribute video highlighted the 'Vagelos Effect' on biomedical science and education. The couple's $400 million gift to Columbia's medical school aims to expand the Vagelos Institute and inspire future scientists.

The 39th AAAI Conference features workshops on AI advancements, including AI for public missions, social impact, urban planning, governance, and more. Topics span from AI in education, cybersecurity, music, to quantum computing, focusing on ethical AI, privacy, and societal benefits. Workshops aim to foster collaboration, share insights, and inspire new research directions in AI.

Bret Rutherford, a former psychiatry researcher at New York State Psychiatric Institute and Columbia University, committed research misconduct by falsely reporting that all subjects met inclusion/exclusion criteria for late-life depression studies, according to the U.S. Office of Research Integrity. Rutherford's false reporting affected the methods and results of five published papers, three of which were retracted and two corrected. He agreed to a three-year ban on U.S. government funding followed by supervised research.

Howard University President Ben Vinson III, Ph.D., inducted into the American Academy of Arts & Sciences, joining 250 members across five divisions. Vinson, a renowned historian of the African diaspora, is the 18th president of Howard University and serves on the Academy’s Commission on the Practice of Democratic Citizenship.

New funding from FDA enables researchers to use wearable sensors for early detection of Huntington's disease signs, focusing on gait and chorea. Led by University of Rochester’s Center for Health + Technology, the study aims to validate digital measures crucial for clinical trial outcomes, potentially impacting other neurological diseases like Parkinson's.

IDEAYA Biosciences to present Phase 1 expansion results of IDE397, a MAT2A inhibitor, at EORTC-NCI-AACR Symposium in Barcelona, focusing on MTAP-deletion urothelial and NSCLC. The company also showcases preclinical data for MAT2A and PARG programs. IDEAYA's financial metrics indicate a market cap of $2.47B, strong liquidity, but negative P/E ratio and revenue decline, reflecting a transitional phase.